BeiGene
BGNE
#963
Rank
A$32.03 B
Marketcap
$282.29
Share price
1.02%
Change (1 day)
8.35%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.02

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$26.61. In 2022 the company made an earnings per share (EPS) of -$30.98 a decrease over its 2021 EPS that were of -$24.33.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.02-19.24%
2022-$30.9827.35%
2021-$24.33-19.96%
2020-$30.3920.81%
2019-$25.1631.52%
2018-$19.13417.57%
2017-$3.70-37.16%
2016-$5.88158.95%
2015-$2.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.60-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.43-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA